The HCAR2 Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the LoVo human colorectal adenocarcinoma line, featuring targeted disruption of the HCAR2 gene. This engineered model abolishes expression of hydroxycarboxylic acid receptor 2 (HCAR2), a G??i/o-coupled receptor activated by endogenous ligands including niacin, butyrate, monomethyl fumarate, and beta-hydroxybutyrate. The polyclonal nature of the knockout population ensures a heterogeneous loss-of-function background, making it a robust tool for investigating HCAR2-dependent signaling without clonal artifacts.
The LoVo parental cell line was established from a metastatic colon adenocarcinoma and is widely employed as a model for colorectal cancer. LoVo cells exhibit characteristic features of aggressive colon carcinoma, including rapid proliferation and metastatic potential. This background provides a physiologically relevant setting to examine how HCAR2 signaling influences colon cancer cell behavior, particularly in the context of tumor suppression and inflammation modulation.
HCAR2 functions as a key mediator of anti-inflammatory and metabolic signaling. Upon ligand binding, it couples to G??i/o proteins to inhibit adenylyl cyclase, decreasing intracellular cAMP levels and attenuating protein kinase A (PKA) activity. This cascade suppresses NF-??B activation, reducing transcription of pro-inflammatory cytokines such as TNF-?? and IL-6. Additionally, HCAR2 recruits ??-arrestin and is regulated by G protein-coupled receptor kinase 2 (GRK2), triggering ERK1/2 signaling downstream. The receptor also influences apoptosis through modulation of Bcl-2 family proteins. In HCAR2 knockout LoVo cells, disruption of this receptor abrogates ligand-dependent cAMP reduction and PKA inhibition, resulting in enhanced NF-??B activity and diminished apoptosis.
In the LoVo colon cancer context, HCAR2 is thought to exert tumor-suppressive effects by maintaining an anti-inflammatory environment and promoting cell death pathways. Loss of HCAR2 potentiates NF-??B-driven gene expression, which may enhance proliferation, survival, and migration??hallmarks of cancer progression. This knockout model thus enables dissection of how niacin and butyrate signaling contributes to colon cancer suppression, as well as identification of downstream effectors such as I??B??, ERK1/2, and Bcl-2 members that mediate the phenotype switch toward a more aggressive state.
Researchers can employ this knockout cell population in a variety of assay formats to explore HCAR2 biology. Typical applications include Western blotting for HCAR2 and its downstream targets, RT-qPCR profiling of inflammatory and apoptotic genes, cAMP accumulation assays to verify receptor coupling, and NF-??B luciferase reporter assays to measure transcriptional activity. Functional studies such as Annexin V/PI apoptosis assays, cell proliferation analysis, and migration/invasion experiments are also feasible, along with transcriptome-wide RNA-seq to characterize global changes. The HCAR2 Knockout LoVo Polyclonal Cells are an indispensable resource for investigating niacin/butyrate signaling in colorectal cancer, GPCR-mediated tumor suppression, and pharmacological modulation of HCAR2. For additional details or custom inquiries, please contact Ascent Research.
